Cephalosporin Drugs Marketembed
Cephalosporin is a large group of antibiotics that belongs to a class known as beta-lactams. Cephalosporin is a wide spectrum bactericidal antibiotic used for the treatment of several bacterial infections.
Cephalosporin Drugs Market Opportunity Analysis, 2019-2026 - Trends and Cephalosporin is a large group of antibiotics that belongs to a class known as beta-lactams. Cephalosporin is a wide spectrum bactericidal antibiotic used for the treatment of several bacterial infections. Cephalosporin drugs are available as both branded and generic medicines. Different generations of cephalosporin are used and preferred for different indications. The third-generation is the most prescribed and broad-spectrum antimicrobial agents useful in a variety of clinical situations. Cefotaxime and ceftizoxime have the best gram-positive bactericidal activity of the third-generation cephalosporin. Ceftazidime and cefoperazone are the only third-generation drugs that provide anti-pseudomonal coverage. Ceftriaxone's long half-life allows for once-daily dosing, making ceftriaxone an excellent drug for outpatient antibiotic therapy of community-acquired infections. Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2893 The global cephalosporin drugs market size was valued at US$ 14,240.0 million in 2018, and is expected to witness a CAGR of 3.8% over the forecast period (2019 – 2026). Report includes chapters which deeply display the following deliverable about industry : • Cephalosporin Drugs Market Research Objective and Assumption • Cephalosporin Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Cephalosporin Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Cephalosporin Drugs Market, By Regions • Cephalosporin Drugs Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Cephalosporin Drugs Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Cephalosporin Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Cephalosporin Drugs Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Increasing Drug Approvals and R&D Activities is expected to Drive Growth of the Cephalosporin Drugs Market Approvals and launch of novel products is expected to be a major factor driving the global cephalosporin drugs market growth over the forecast period. For instance, in June 2019, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for the use of ZERBAXA (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Increasing research and development activities has spurred growth of the cephalosporin drugs market. For instance, in November 2017, B. Braun Medical Inc. initiated a clinical trial of Cefazolin infusion evaluating the safety of 1 g and 2 g of Cefazolin in pediatric subjects. The study is in phase 4 and is expected to be completed in July 2019. Therefore, increasing research on cephalosporin drugs is expected to create a favorable environment for the cephalosporin drugs market growth over the forecast period. Market Dynamics Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015. However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations. Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/market-insight/cephalosporin-drugs-market-2893 Key players operating in the global cephalosporin drugs market include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG. About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]